Novavax says its COVID-19 vaccine prevents severe cases from U.K., South African variants
Novavax announced Thursday that its COVID-19 vaccine had proved effective, especially at preventing serious illness or death, in late-stage trials in Britain and South Africa, home to two of the more contagious variants spreading around the world.
The Maryland biotech firm said that its final analysis of its British trial found the vaccine 96 percent effective against the original strain and 86 percent effective against the B.1.1.7 variant, for an overall protection rate of 90 percent. In the smaller South African trial, the vaccine was 55 percent effective at preventing COVID-19 cases among people without HIV, and 49 percent effective when the HIV-positive subset was included. There were zero cases of severe illness in either country among trial participants who got the vaccine, Novavax said, versus 10 severe cases in people given placebos.
"A trend we're seeing, even with these variants, is that these vaccines are retaining high efficacy against severe disease," Kathleen Neuzil, director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, tells The Washington Post. "I really loved seeing the 100 percent efficacy against severe disease."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The results, mostly in line with a preliminary analysis from January, have not yet been peer-reviewed or published. But Novavax says it will submit them to regulatory agencies around the world, including in Britain and the U.S. The company expects its 30,000-person trial in the U.S. and Mexico to wrap up by early April. If the Food and Drug Administration accepts the data from the U.K. study, Novavax says, its vaccine could get U.S. approval as soon as May. Otherwise, it could be several months before the U.S. gives it the green light.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
The magician who secretly smashed the Magic Circle's glass ceiling
Under The Radar Sophie Lloyd lurked in the all-male society by posing as a teenage boy for nearly two years, but was expelled after revealing her true identity
By Chas Newkey-Burden, The Week UK Published
-
Kate Summerscale's 6 favorite true crime books about real murder cases
Feature The best-selling author recommends works by Helen Garner, Gwen Adshead, and more
By The Week US Published
-
Team of bitter rivals
Opinion Will internal tensions tear apart Trump's unlikely alliance?
By Theunis Bates Published
-
Boeing machinists approve contract, end strike
Speed Read The company's largest union approved the new contract offer, ending a seven-week strike
By Peter Weber, The Week US Published
-
US economy still strong in final preelection report
Speed Read It grew at a solid 2.8% annual rate from July through September
By Peter Weber, The Week US Published
-
Boeing machinists reject deal, continue strike
Speed Read The rejection came the same day Boeing reported a $6.2 billion quarterly loss
By Peter Weber, The Week US Published
-
Ports reopen after dockworkers halt strike
Speed Read The 36 ports that closed this week, from Maine to Texas, will start reopening today
By Peter Weber, The Week US Published
-
Empty-nest boomers aren't selling their big homes
Speed Read Most Americans 60 and older do not intend to move, according to a recent survey
By Peter Weber, The Week US Published
-
Brazil accuses Musk of 'disinformation campaign'
Speed Read A Brazilian Supreme Court judge has opened an inquiry into Elon Musk and X
By Rafi Schwartz, The Week US Published
-
Disney board fends off Peltz infiltration bid
Speed Read Disney CEO Bob Iger has defeated activist investor Nelson Peltz in a contentious proxy battle
By Rafi Schwartz, The Week US Published
-
Disney and DeSantis reach detente
Speed Read The Florida governor and Disney settle a yearslong litigation over control of the tourism district
By Peter Weber, The Week US Published